FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3700068014 | Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3700069018 | Scopolamine hydrobromide 300 microgram oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3700070017 | Hyoscine hydrobromide 300 microgram oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Is a | Scopolamine hydrobromide | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Is a | Hyoscine | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Scopolamine (substance) | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Is a | Hyoscine hydrobromide | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Scopolamine hydrobromide (substance) | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Is a | Scopolamine hydrobromide | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Oral tablet | true | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Is a | Hyoscine-containing product in oral dose form | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Scopolamine hydrobromide (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Scopolamine hydrobromide (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 300 | false | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mcg | true | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 0.3 | false | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | false | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Scopolamine hydrobromide (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Count of base of active ingredient | un | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Is a | Hyoscine only product in oral dose form | true | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Plays role | Antiemetic therapeutic role (role) | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets